Altimmune, Inc. (ALT) Financial Statements (2026 and earlier)

Company Profile

Business Address 910 CLOPPER ROAD
GAITHERSBURG, MD 20878
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments273,456210,776183,105149,826131,891139,380
Cash and cash equivalent43,76061,236183,10549,10436,92631,474
Short-term investments229,696149,540 100,72294,965107,906
Restricted cash and investments424242424242
Receivables 700 400 300
Other undisclosed current assets4,6945,0975,2754,9945,3216,037
Total current assets:278,192216,615188,422155,262137,254145,759
Noncurrent Assets
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization312337364384413446
Other noncurrent assets1,4251,4951,5641,6171,6391,659
Total noncurrent assets:1,7371,8321,9282,0012,0522,105
TOTAL ASSETS:279,929218,447190,350157,263139,306147,864
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8,6317,7953,5572,5883,7463,828
Accounts payable2,7174,8048511,0772111,133
Accrued liabilities5,9142,9912,7061,5113,5352,695
Other undisclosed current liabilities6,3664,8115,6637,2106,7224,810
Total current liabilities:14,99712,6069,2209,79810,4688,638
Noncurrent Liabilities
Long-term debt and lease obligation34,28714,44514,332   
Long-term debt, excluding current maturities34,28714,44514,332   
Liabilities, other than long-term debt5,7535,7955,4311,3581,4241,486
Other liabilities5,7535,7955,431162226
Operating lease, liability    1,3421,4021,460
Other undisclosed noncurrent liabilities    3,9453,9064,363
Total noncurrent liabilities:40,04020,24019,7635,3035,3305,849
Total liabilities:55,03732,84628,98315,10115,79814,487
Equity
Equity, attributable to parent224,892185,601161,367142,162123,508133,377
Common stock11109877
Additional paid in capital879,292812,732769,508728,122689,864676,425
Accumulated other comprehensive loss(4,928)(5,016)(5,039)(5,003)(4,973)(4,845)
Accumulated deficit(649,483)(622,125)(603,111)(580,965)(561,390)(538,210)
Total equity:224,892185,601161,367142,162123,508133,377
TOTAL LIABILITIES AND EQUITY:279,929218,447190,350157,263139,306147,864

Income Statement (P&L) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Revenues 2655555
Gross profit: 2655555
Operating expenses(28,919)(20,864)(22,927)(21,820)(24,871)(24,772)
Operating loss:(28,893)(20,859)(22,922)(21,815)(24,866)(24,767)
Nonoperating income1,5351,8457761,5591,6861,922
Investment income, nonoperating2,4382,4261,1321,5451,5691,910
Interest and debt expense(876)(495)(264)(1)(1)(6)
Loss from continuing operations before equity method investments, income taxes:(28,234)(19,509)(22,410)(20,257)(23,181)(22,851)
Other undisclosed income from continuing operations before income taxes87649526419 
Loss from continuing operations before income taxes:(27,358)(19,014)(22,146)(20,256)(23,172)(22,851)
Income tax benefit    681  
Loss from continuing operations:(27,358)(19,014)(22,146)(19,575)(23,172)(22,851)
Other undisclosed net loss     (8) 
Net loss:(27,358)(19,014)(22,146)(19,575)(23,180)(22,851)
Other undisclosed net income attributable to parent      6
Net loss available to common stockholders, diluted:(27,358)(19,014)(22,146)(19,575)(23,180)(22,845)

Comprehensive Income ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net loss:(27,358)(19,014)(22,146)(19,575)(23,180)(22,851)
Other undisclosed comprehensive income (loss)8823(36)(30)(128)353
Comprehensive loss, net of tax, attributable to parent:(27,270)(18,991)(22,182)(19,605)(23,308)(22,498)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: